"There is no deal between AstraZeneca and BMS. There never was a deal to be done, and there are no discussions between the companies," the source told Reuters on Wednesday, speaking on condition of anonymity. Wednesday's rebound partially reverses what had been AZN's biggest one-day drop since 2020, triggered by reports published on Sunday, August 3 by the Financial Times. The scale of the mooted transaction had already strained credulity across the investment community. AstraZeneca shareholders were particularly cool on the idea.